Neurogene CEO exercises options for 756 shares

The chief executive officer's reported direct common-stock holdings include RSUs scheduled to vest in installments through February 20, 2029.

Rhea-AI Filing Summary

Neurogene Inc. (NGNE) CEO Rachel McMinn exercised a fully vested option covering 756 shares on September 22, 2026, acquiring 756 common shares at an exercise price of $25.32 per share. Her reported direct common-stock holdings afterward were 1,345,063 shares, including 15,933 RSUs and 25,900 RSUs. No Rule 10b5-1 plan is reported.

Insider Trade Summary

756 shares exercised/converted

Exercise 2 txns

Insider McMinn Rachel

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F2	756	$0.00	$0.00
Exercise	Common Stock F1	756	$25.32	$19K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 1,345,063 shares (Direct)

Footnotes (2)

1. F1. Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.
2. F2. This option is fully vested and exercisable.

Key Figures

Common shares acquired: 756 shares Option exercise price: $25.32 per share Direct common shares following transaction: 1,345,063 shares +2 more

5 metrics

Common shares acquired 756 shares Through option exercise on September 22, 2026

Option exercise price $25.32 per share September 22, 2026

Direct common shares following transaction 1,345,063 shares Reported after the September 22, 2026 transaction; includes RSUs

Restricted stock units 15,933 RSUs Vest in equal installments on March 23, 2027 and March 23, 2028

Restricted stock units 25,900 RSUs Vest in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029

Key Terms

Stock Option (Right to Buy), restricted stock units, fully vested and exercisable

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

restricted stock units financial

"15,933 restricted stock units that vest annually in equal installments"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

fully vested and exercisable financial

"This option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Neurogene CEO Rachel McMinn acquire in the option exercise?

Rachel McMinn exercised an option to acquire 756 Neurogene common shares on September 22, 2026, at an exercise price of $25.32 per share.

When are the RSUs included in Rachel McMinn's NGNE holdings scheduled to vest?

The 15,933 RSUs vest in equal installments on March 23, 2027 and March 23, 2028. The 25,900 RSUs vest in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 02:49 PM Accepted by SEC EDGAR 10/02/2026 - 02:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McMinn Rachel

(Last) (First) (Middle)

C/O NEUROGENE INC.

535 W 24TH STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neurogene Inc. [ NGNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2026		M		756	A	$25.32	1,345,063(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.32	09/22/2026		M			756	(2)	09/22/2026	Common Stock	756	$0	0	D

Explanation of Responses:

1. Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.

2. This option is fully vested and exercisable.

Remarks:

	/s/ Donna M. Cochener, as attorney-in-fact for Rachel McMinn	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)